drugset / Trial / NCT00475410

Efficacy and Safety of Adipose Stem Cells to Treat Complex Perianal Fistulas Not Associated to Crohn´s Disease

NCT00475410 ↗

Phase 3 Completed 214 enrolled Tigenix S.A.U.
RandomizedParallel-groupDouble-blindTreatment

Summary

Anal fistula is defined as an abnormal communication between the anal canal and the perianal skin. Adipose-derived stem cells are a new therapy for the closure of these fistulas. This study will test the safety and efficacy of ASCs (adipose stem cells) in the treatment of patients without Crohn´s disease.

Timeline

Start
2007-02
Primary completion
2009-08
Completion
2009-08

Outcome

Missed primary endpoint

paper After 24 to 26 weeks, the healing rate was 39.1%, 43.3%, 37.3% in groups A, B, and C (p = 0.79). PMID 22706128 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Cx401 Unknown 2e+07 cells —
Subject Fibrin adhesive Unknown — —

Indications